image credit: Unsplash

CNS Pharmaceuticals Begins Manufacturing of Berubicin in Europe

October 9, 2020

Via: BioSpace

CNS PHARMACEUTICALS AG, (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that the Company’s European manufacturer, BSP Pharmaceuticals S.p.A. (“BSP”), has begun the manufacturing process for Berubicin Drug Product, its lead drug candidate for the treatment of glioblastoma multiforme (GBM), an aggressive form of brain cancer currently considered incurable.

Read More on BioSpace